

Yoshihito Kano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1202584/publications.pdf>

Version: 2024-02-01

28
papers

761
citations

687220

13
h-index

642610

23
g-index

30
all docs

30
docs citations

30
times ranked

1082
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 124, 105666.	0.8	2
2	Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study. <i>PLoS ONE</i> , 2022, 17, e0266112.	1.1	13
3	Primary pulmonary choriocarcinoma with a genomic sequence. <i>Pathology International</i> , 2022, 72, 141-143.	0.6	6
4	Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 3476.	1.7	9
5	PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 22.	3.5	37
6	ASO Author Reflections: Impact of Liquid Biopsy Using Plasma Cell-Free DNA in Solid Tumors in Japan. <i>Annals of Surgical Oncology</i> , 2021, 28, 8506-8507.	0.7	2
7	A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). <i>Annals of Surgical Oncology</i> , 2021, 28, 8497-8505.	0.7	8
8	Intestinal phenotype is maintained by Atoh1 in the cancer region of intraductal papillary mucinous neoplasm. <i>Cancer Science</i> , 2021, 112, 932-944.	1.7	4
9	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. <i>Nature Communications</i> , 2021, 12, 6274.	5.8	22
10	The clinical utility of comprehensive genomic profiling for recurrent / metastatic head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2021, 47, 359-365.	0.0	0
11	<i>NRAS</i> Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 3413-3423.	0.4	40
12	Clinical impact of hemizygous deletion detection and panel-size in comprehensive genomic profiling.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15671-e15671.	0.8	0
13	A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding. <i>Molecular Cancer Research</i> , 2019, 17, 2306-2314.	1.5	19
14	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. <i>Nature Communications</i> , 2019, 10, 224.	5.8	66
15	Abstract 3123: Targeting SHP2 and RAS MAPK pathway in neuroblastoma. , 2019, , .		0
16	Abstract 4360: Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer. , 2018, , .		14
17	New structural and functional insight into the regulation of Ras. <i>Seminars in Cell and Developmental Biology</i> , 2016, 58, 70-78.	2.3	22
18	Abstract B13: Novel treatment strategy for pancreatic cancer by targeting the "undruggable" Ras oncoprotein. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
19	Atonal homolog 1 protein stabilized by tumor necrosis factor $\hat{\pm}$ induces high malignant potential in colon cancer cell line. <i>Cancer Science</i> , 2015, 106, 1000-1007.	1.7	20
20	Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. <i>Nature Communications</i> , 2015, 6, 8859.	5.8	173
21	Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule. <i>Clinical Journal of Gastroenterology</i> , 2014, 7, 449-454.	0.4	9
22	Fluorescent labelling of intestinal epithelial cells reveals independent long-lived intestinal stem cells in a crypt. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 493-499.	1.0	10
23	Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3785-94.	3.3	81
24	Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 840-846.	1.0	43
25	The acquisition of malignant potential in colon cancer is regulated by the stabilization of Atonal homolog 1 protein. <i>Biochemical and Biophysical Research Communications</i> , 2013, 432, 175-181.	1.0	19
26	Improved Bioavailability of a Water-Insoluble Drug by Inhalation of Drug-Containing Maltosyl- β -Cyclodextrin Microspheres Using a Four-Fluid Nozzle Spray Drier. <i>AAPS PharmSciTech</i> , 2012, 13, 1130-1137.	1.5	8
27	Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4. <i>Journal of Gastroenterology</i> , 2011, 46, 191-202.	2.3	17
28	Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2251-2260.	0.9	117